Happy to share the results of our international research project on Ku+ myositis: new insights👀 in characteristics & pathophysiology of the rare IIM subtype! Thanks to all cooperation partners, patients participating, @rheumadocs & DGMe.V. for the support
rdcu.be/dN1Tj
Anti-Ku + myositis: an acquired inflammatory protein-aggregate myopathy. 92% female, median age 56yrs w/ very hi CK levels, 31% have overlap w/ scleroderma (half of these have ILD). Path shows by myofiber necrosis, MHC-class I/II+, endomysial inflammation buff.ly/4dcV6Jo
1
6
574
Special thanks to my mentors @KruscheMartin, @UdoSchn20101688, Werner Stenzel and Corinna Preuße for letting me catch 🔥 with #myositis in the first place!
1
229
New evidence, that autoantibodies in #myositis might play a central role in pathophysiology! Milestone work by the team of and around @DrIagoPinal, Sandra, Maria and Andy.👏
Pathological autoantibody internalisation in myositis ard.bmj.com/content/early/20…
2
196
Happy we could share our research results on #Kumyositis pathogenesis at #GCOM24. So greatful for my mentors, our team and collaborators as well as all patients that participate in #myositis #research!
@rheumadocs
@KruscheMartin
5
519
Thank you for having us at your lab Andy, @DrIagoPinal, @MariaCasalD, Sandra and Katherine @NIH! We enjoyed the inspiring and joyful discussions on #myositis and are looking forward to continue our collaborations! See you at #GCOM2024!
Great work by my colleague @nikolasruffer and our Hamburg-Berlin Muscle group:
Approaching new therapeutic options with #musclebiopsies in refractory #myositis.
This Post is from an account that no longer exists. Learn more
Happy to share our systematic review on daratumumab usage in 24 different autoimmune diseases published in @ARD_BMJ
rmdopen.bmj.com/lookup/pmidl…
@KruscheMartin @nikolasruffer @Tobias_B_Huber @lost_endorf @DGRh_Tweets @rheumadocs
• 38 publications incl. 83 patients with rheumatological, nephrological, hematological & neurological diseases
• mainly therapy refractory cases (median of 5 different previous therapies)
• remission/improvement in 81%
• Antibody depletion/reduction in 52%
1
1
179
What an amazing weekend! I am very happy I could participate in this #ENMC workshop together with all these great interdisciplinary experts and a patients' representative to discuss dedicatedly on #antisynthetase syndrome!
Fascinating publication on unique microRNA in different IIM-subtypes, complementing the known unique subtypes of histopathology and transcriptomics in Cells' special issue on NMDs.
Curious how future research will elucidate aspects in myositis-overlap-syndromes.
#myositis #CTD
Identification of Unique microRNA Profiles in Different Types of Idiopathic Inflammatory Myopathy. Cells 2023.
Muscle biopsies from DM, AS, and IBM patients have unique miRNA signatures. These miRNAs may be key to understand myositis pathogenesis.
doi.org/10.3390/cells1217219…
5
489
M.-T.Holzer retweeted
Kommt zum AGJR Stand und macht an der spannende Umfrage zum Thema künstliche Intelligenz im ärztlichen Alltag mit 🧠 belohnt werdet Ihr mit leckerem Popcorn 🍿 Etage +1 im Rheumahaus @KruscheMartin @ChristinaDusing @JC_rhmtlgy @DGRh_Tweets
M.-T.Holzer retweeted
🔭 Intriguing viewpoint by @nikolasruffer & @KruscheMartin on #VEXASsyndrome: A diagnostic puzzle 🎨
〰️ “Normals” teach us rules; “outliers” teach us laws 〰️
➡️ More #inflammatorydiseases caused by #somaticmutations will explain yet unsolved puzzles
bit.ly/3YsHnrk
Extremely delighted to share our results of the international web-based survey on healthcare utilization & unmet needs of patients w #antisynthetase syndrome
rdcu.be/dgWkv
Special thanks to our colleagues & all patients for participating!
@JK77775
@digital_rheuma
#ASSD














